NASDAQ: PTIXProtagenic Therapeutics Inc Stock
$3.03-0.09 (-2.88%)
Updated May 16, 2025
PTIX Price
$3.03
Fair Value Price
$0.38
Market Cap
$1.78M
52 Week Low
$2.35
52 Week High
$26.18
P/E
-0.23x
P/B
-20.2x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$5.24M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-12.19
Operating Cash Flow
-$4M
Beta
-0.16
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
PTIX Overview
Protagenic Therapeutics, Inc. is a biotechnology company developing naturally occurring human brain hormones for the treatment of anxiety and depression based mood disorders. It uses a search algorithm to identify new bioactive peptides in the genome. The company's lead product candidate, PT00114, is targeted to inhibit anxiety and depression without interfering with normal brain function. Protagenic Therapeutics was founded in 2004 and is headquartered in New York, NY.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PTIX's potential to beat the market
- PTIX doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
PTIX
RankedUnranked of 456
RankedUnranked of 456
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $46.01 | A | |
| $8.19 | A | |
| $63.31 | A |
Be the first to know about important PTIX news, forecast changes, insider trades & much more!
PTIX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PTIX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PTIX ($3.03) is overvalued by 707.57% relative to our estimate of its Fair Value price of $0.38 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
PTIX ($3.03) is not significantly undervalued (707.57%) relative to our estimate of its Fair Value price of $0.38 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
PTIX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PTIX due diligence checks available for Premium users.
Valuation
PTIX fair value
Fair Value of PTIX stock based on Discounted Cash Flow (DCF)
Price
$3.03
Fair Value
$0.38
Overvalued by
707.57%
PTIX ($3.03) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PTIX ($3.03) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PTIX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PTIX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.23x
Industry
-154.88x
Market
25.95x
PTIX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-20.2x
Industry
4.21x
PTIX's financial health
Profit margin
Revenue
$0.0
Net Income
-$1.4M
Profit Margin
0%
PTIX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$988.7k
Liabilities
$1.1M
Debt to equity
-12.19
PTIX's short-term liabilities ($1.08M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PTIX's short-term assets ($928.18k) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PTIX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PTIX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.1M
Investing
$0.0
Financing
$102.5k
PTIX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PTIX vs Biotech Stocks
Protagenic Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.